IDEXX LaboratoriesFRA:IX1 +1.38%96 Days Payable is 26.08 as of Mar. 2026, which is 0% above its 10-year median of 25.98. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €554.46 (Modestly Undervalued). Among 190 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 84.21% on this metric.
The historical rank and industry rank for IDEXX Laboratories's Days Payable or its related term are showing as below:
FRA:IX1'
s Days Payable Range Over the Past 10 Years
Min: 23.58 Med: 25.98 Max: 30.31
Current: 25.93
During the past 13 years, IDEXX Laboratories's highest Days Payable was 30.31. The lowest was 23.58. And the median was 25.98.
FRA:IX1's Days Payable is ranked worse than 84.21% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs FRA:IX1: 25.93
IDEXX Laboratories's Days Payable
declined
from Mar. 2025 (28.95) to Mar. 2026 (26.08).
It may suggest that IDEXX Laboratoriesaccelerated paying its suppliers.
IDEXX Laboratories Days Payable Related Terms
IDEXX Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
IDEXX Laboratories's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a Days Payable of 26.08 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IDEXX Laboratories and its competitors. This is near median its historical median of 25.98. Over the past decade, IDEXX Laboratories' Days Payable has ranged from 23.58 to 30.31. According to the industry distribution chart, IDEXX Laboratories ranks #160 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 84.2%.
Is IDEXX Laboratories' Days Payable too high?
IDEXX Laboratories' current Days Payable of 26.08 is near median its 10-year median of 25.98. Over the past 10 years, this metric has ranged from a low of 23.58 to a high of 30.31. The Medical Diagnostics & Research industry median Days Payable is 67.28. IDEXX Laboratories' value of 26.08 is 61.2% below this industry median. Based on the distribution chart, IDEXX Laboratories ranks #160 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Days Payable compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #160 out of 190 companies for Days Payable. This places IDEXX Laboratories in the lower half of its industry. The industry median Days Payable is 67.28. IDEXX Laboratories' value of 26.08 is 61.2% below this benchmark. Historically, IDEXX Laboratories' own Days Payable has ranged from 23.58 to 30.31 over the past decade. While the company's 10-year median is 25.98 vs. the industry median of 67.28, IDEXX Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Days Payable of 26.08 is 61.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Days Payable is 26.08, which is near median its own 10-year median of 25.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €554.46, compared to a current price of €484.70 — trading 12.6% below its estimated fair value. The current Days Payable is 26.08, which is near median its 10-year median of 25.98 and 61.2% below the Medical Diagnostics & Research industry median of 67.28. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Days Payable is 26.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €484.70 is trading 12.6% below its estimated GF Value™ of €554.46.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Days Payable: 26.08 (near median its 10-year median of 25.98)
GF Value™: €554.46 vs. price of €484.70 (12.6% below fair value)
Industry Position: 61.2% below the Medical Diagnostics & Research median (#160 of 190)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
